Lanzhou Institute Of Biological Products Co., Ltd.

No.888, Yanchang Road, Chengguan District, Lanzhou, Gansu, China

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

42.9%

Phase 3

42.9%

Phase 2

14.3%

Trial Status Distribution

Completed

14.3%

Enrolling By Invitation

14.3%

Not yet recruiting

14.3%

Unknown

57.1%

Clinical Trials

Trials sponsored by this organization (7)

A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

Phase 2

Not yet recruiting

interventional

Jan 2026200 participants

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

Phase 1

Enrolling By Invitation

interventional

Aug 202568 participants

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1

Unknown

interventional

Dec 202171 participants

A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)

Phase 3

Unknown

interventional

Mar 2016216 participants

A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine

Phase 1

Unknown

interventional

Jun 2015200 participants

A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine

Phase 3

Unknown

interventional

Sep 2014288 participants

A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

Phase 3

Completed

interventional

Jul 2014180 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations